Literature DB >> 9241658

Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians.

R A McLellan1, M Oscarson, J Seidegård, D A Evans, M Ingelman-Sundberg.   

Abstract

The polymorphic cytochrome P450 2D6 (CYP2D6) causing poor, extensive or ultrarapid metabolism of several clinically important drugs exhibits pronounced interethnic variation. Ultrarapid metabolism is caused by multiple copies of active CYP2D6 genes and recently 29% of an Ethiopian population has been shown to carry duplicated or multiduplicated CYP2D6 genes, whereas the corresponding frequency in other black, Oriental and European populations investigated is 1-2%. In order to characterize the distribution of alleles with multiple CYP2D6 copies in a neighbouring population and to characterize the CYP2D locus in general among Saudi Arabians, the CYP2D6 genotype of a Saudi Arabian population was examined using restriction fragment length polymorphism (RFLP) analysis and allele-specific polymerase chain reaction (PCR) amplification. Of 101 Saudi Arabians studied, 21 subjects had an EcoRI fragment indicative of CYP2D6 gene duplication. In contrast, only two individuals were heterozygous for a deletion of the whole gene (CYP2D6*5). The allele frequency of CYP2D6*4, the most common defective allele among Caucasians, was only 3.5% in the Saudi population. Two other alleles, CYP2D6*10 and *17, common in certain populations and which cause diminished enzyme activity, were found only at low allele frequencies of 3.0% each. These findings are in agreement with earlier Saudi Arabian phenotyping studies which reported a low frequency (1-2%) of poor metabolizers for CYP2D6 probe drugs. In conclusion, the Saudi Arabian population studied exhibited very few defective alleles and a large number of subjects carried duplicated CYP2D6 genes, implying a high conservation on functional CYP2D6 genes possibly due to dietary reasons and reveal the Saudi Arabians as an unique population in comparison with others examined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9241658     DOI: 10.1097/00008571-199706000-00003

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  36 in total

Review 1.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

2.  CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.

Authors:  Marisol López; Jorge Guerrero; Helgi Jung-Cook; María Elisa Alonso
Journal:  Eur J Clin Pharmacol       Date:  2005-10-26       Impact factor: 2.953

Review 3.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

Review 4.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility.

Authors:  Ya-Ping Luo; Han-Chun Chen; Md Asaduzzaman Khan; Fang-Zhi Chen; Xin-Xing Wan; Bo Tan; Fang-Dan Ou-Yang; Dian-Zheng Zhang
Journal:  Tumour Biol       Date:  2010-09-29

6.  CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess.

Authors:  Nicolas von Ahsen; Mladen Tzvetkov; Harin A Karunajeewa; Servina Gomorrai; Alice Ura; Jürgen Brockmöller; Timothy M E Davis; Ivo Mueller; Kenneth F Ilett; Michael Oellerich
Journal:  Int J Mol Epidemiol Genet       Date:  2010-08-18

7.  Distribution of arylamine N-acetyltransferase 2 (nat2) genotypes among Omanis.

Authors:  Musbah O M Tanira; Mehmet Simsek; Khalid Al Balushi; Khulood Al Lawatia; Hameedah Al Barawani; Riad A Bayoumi
Journal:  J Sci Res Med Sci       Date:  2003-08

Review 8.  Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Authors:  Katarzyna Drozda; Daniel J Müller; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2014-02       Impact factor: 4.705

9.  An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.

Authors:  S Verma; S Sehdev; A Joy; Y Madarnas; J Younus; J A Roy
Journal:  Curr Oncol       Date:  2009-07       Impact factor: 3.677

10.  Management of postoperative nausea and vomiting: focus on palonosetron.

Authors:  Neil A Muchatuta; Michael J Paech
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.